ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / EYPT / insiders
PRPO (30) RPID (34) HBIO (47) BNGO (29) ⌘ Pro Terminal β†’

EyePoint Inc. (EYPT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.37 +7.58% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.37

EyePoint Inc. (EYPT) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (26/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE E β€’ RED ALERT Cap $30.0M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EYPT Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is EYPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, EyePoint Inc. (NASDAQ: EYPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $0.37 (+7.58% 1D, market cap $30.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EYPT ranks #916 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does EYPT compare to PRPO and RPID in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), EYPT carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, PRPO (Precipio Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -7.9%, cap $32.4M) and RPID (Rapid Micro Biosystems Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.9M). Among the 5-stock peer group, EYPT leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EYPT?
β–Ό

Per EYPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001314102), EyePoint Inc. generated $31.4M in revenue (-27.5% YoY), -$232.0M in net income, and -$243.4M in free cash flow against $364.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.37 (+1.17%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (26/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510026
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D-
Cash (6)Whales (3)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.5% Base Target
$20 Bull$0 Base$0 Bear
πŸ“¬ FREE EYPT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for EYPT)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (26/100 Composite)
πŸ” WHY EYPT SCORES 26/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 1/9

β–² #2 Bullish Driver: Cash Engine Quality+6/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
34
Grade E$3.07-86.6% Next Q
Q2 (-2Q)
31
Grade E$0.41-12.2% Next Q
Q3 (-1Q)
29
Grade E$0.36+2.8% Next Q
Current
26
Grade E$0.37-10.5% Hist 90D Ξ±
Trajectory: E (34) β†’ E (26)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a EYPT Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While EYPT currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.02) and Max Pain ($0.39) forces dealer call-delta covering toward $20.07.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EYPTβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œEYPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 26%NO 74%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

EYPT Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (EYPT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on EYPT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EYPT)

  • βœ“Walkthrough of EYPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
EYPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -97.33%β–Ό DESCENDING CHANNEL
2026-11-03O $0.38H $0.38L $0.35C $0.37VOL 6.12M
RES: $12.66SUP: $-2.77SMA50: $3.02SMA200: $10.83
$17.01$12.49$7.97$3.46$-1.06RES $12.66SUP $-2.77$0.372026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EYPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ EYPT Butterfly Map β†’ + Track EYPT β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -27.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EYPT today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for EYPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EYPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EYPT)

Health Care Rank #916 of 1016 βš”οΈ PRPO vs EYPT Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (EYPT vs. PRPO, RPID, HBIO, BNGO)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, EyePoint Inc. (EYPT) ranks #916 by composite RQD confidence (26/100, grade E) and #796 by equity capitalization ($30.0M). Within this direct 5-issuer industry benchmark cohort, EYPT leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. HBIO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with EYPT at 26/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EYPT ACTIVE
EyePoint Inc.
E 26/100 β€” β€” -35.0% +7.58% $30.0M Benchmark Subject
PRPO
Precipio Inc.
E 30/100 β€” 44.2% -7.9% -1.71% $32.4M /prpo-vs-eypt β†’
RPID
Rapid Micro Biosystems Inc. (Class A)
E 34/100 β€” β€” -35.0% -4.50% $36.9M /rpid-vs-eypt β†’
HBIO
Harvard Bioscience Inc.
D 47/100 β€” 57.7% -35.0% -3.37% $40.5M /hbio-vs-eypt β†’
BNGO
Bionano Genomics Inc.
E 29/100 β€” 46.3% -35.0% +0.87% $16.1M /bngo-vs-eypt β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001314102

In its most recent audited fiscal period (FY2025, filed 2025-12-31), EyePoint Inc. (EYPT) reported GAAP revenue of $31.4M (-27.5% vs. FY2024 revenue of $43.3M , and -31.8% cumulative change since FY2023) , GAAP net income of -$232.0M, operating cash flow of -$240.1M, and free cash flow of -$243.4M (-86.8% YoY). On the balance sheet, EYPT closed FY2025 with $364.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $31.4M -$232.0M -$240.1M -$243.4M $364.0M β€”
FY2024 (FY) 2024-12-31 $43.3M -$130.9M -$126.2M -$130.3M $418.5M β€”
FY2023 (FY) 2023-12-31 $46.0M -$70.8M $1.9M $1.9M β€” β€”

3. EYPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EYPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, EyePoint Inc. (NASDAQ: EYPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $0.37 (+7.58% 1D, market cap $30.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EYPT ranks #916 in composite RQD confidence.

How does EYPT compare to PRPO and RPID in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), EYPT carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, PRPO (Precipio Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -7.9%, cap $32.4M) and RPID (Rapid Micro Biosystems Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.9M). Among the 5-stock peer group, EYPT leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EYPT?

Per EYPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001314102), EyePoint Inc. generated $31.4M in revenue (-27.5% YoY), -$232.0M in net income, and -$243.4M in free cash flow against $364.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EYPT trading relative to its 50-day, 200-day, and 52-week technical levels?

EYPT last traded at $0.37 (+7.58% on volume of 6,327,753 shares), positioning the stock -87.75% below its 50-day simple moving average ($3.02) and -96.58% below its 200-day simple moving average ($10.83). Across its 52-week range of $0.34 to $19.11, EYPT sits at the 0.2% percentile with a 14-day RSI of 16.5 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.00 to $0.42).

Direct Sub-Reports: EYPT RQD Cockpit EYPT 12M Forecast EYPT Earnings & Move EYPT Dividends & DRIP EYPT Insiders & 13F EYPT Whale Options EYPT Profit Sankey EYPT News & Why
ROARABLE RATING BRIEF β€’ RQD 26/100 (E) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

EYPT β€” EyePoint Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:48:22Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

EYPT scores 26 out of 100 with a letter grade of E, labeled "Roarable Strong Sell β€” Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 6 / 20 (ROIC -35%; FCF yield 0%), Whale 13F Flow scores 3 / 20, Insider Conviction scores 3 / 20, Macro Regime Fit scores 6 / 20 (Beta 1.0), and Forensic Balance Sheet scores 8 / 20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are institutional and insider conviction, which signal little supportive positioning, and the cash engine, which shows negative returns on capital and no free-cash-flow yield. The balance sheet pillar is comparatively less weak but still scores low on the Piotroski test.

2. Business Model, Unit Margins & SEC Financial Trajectory

EyePoint Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Laboratory Analytical Instruments, . Reported revenue declined from $46.0M (FY 2023) to $43.3M (FY 2024) to $31.4M (FY 2025). Other details of how the company makes money are β€”

The company reported losses in each period shown, with FY 2025 net income of -$232.0M. And market data, operating margin and net margin are each -60%, gross margin is 0%, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, with Debt/Equity of 0.5. The reported cash balance of $101.8M for FY 2025 compares with a market capitalization of $32.8M per the market data.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case: The reported $101.8M of FY 2025 cash exceeds the $32.8M market capitalization. With Fundamental Cash Engine at 6/20 (ROIC -35.0%, FCF yield β€”) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $0.34 – $19.11 52-week range.
  • 🐻 Primary Bear Case: FY 2025 free cash flow of -$243.4M and a 26 RQD score point to a severe forensic risk profile. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Laboratory Analytical Instruments (Health Care), EYPT carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: What products or technologies generate EyePoint's $31.4M of FY 2025 revenue, and who are its customers?
  • Key Question #2: What is the status and timeline of the Duravyu program referenced in the news wire, and what did the trial setback specifically show?
  • Key Question #3: What is the company's cash runway given $101.8M of reported cash against FY 2025 free cash flow of -$243.4M?

EYPT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for EyePoint Inc. (EYPT) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to EYPT Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EYPT Bull vs. Bear Conversation Board β€” What's Your Call at $0.37?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EYPT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on EYPT:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $0.43 (+22.9%)
πŸ“Œ Pinned Debate

The reported $101.8M of FY 2025 cash exceeds the $32.8M market capitalization.

Here is why I am bullish on EYPT here at $0.35: The reported $101.8M of FY 2025 cash exceeds the $32.8M market capitalization.. Compare EYPT's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Laboratory Analytical Instruments. As long as cash conversion holds up, dips toward $0.33 are getting bought.

EarningsSniper πŸ‚ BULL

Both sides have a point here β€” EYPT's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RI RiskArb_Desk Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.27 (-22.9%)
Spot @ $0.35

FY 2025 free cash flow of -$243.4M and a 26 RQD score point to a severe forensic risk profile.

I respect the product at EyePoint Inc., but the stock at $0.35 is a different story. FY 2025 free cash flow of -$243.4M and a 26 RQD score point to a severe forensic risk profile.. FCF yield is 0.0% and RQD sits at 26/100 (E) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%